Article in Infection and immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Ashley M GroshongDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Nora E GibbonsDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Brendan P MooreDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
William T BellamyDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Jon S BlevinsDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0001-6216-7365
Funding
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Pilot Grant ProgramP30GM145393 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI MARK S SMELTZER · 2022 to 2026
$7.6M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
RpoS-mediated virulence regulation in Borrelia burgdorferiR01AI087678 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI BLEVINS, JON SCOTT · 2010 to 2014
$1.8M
Rrp2-dependent gene regulation in Borrelia burgdorferiR21AI119532 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI BLEVINS, JON SCOTT · 2015 to 2016
$403k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI087678, R21AI119532HHS | NIH | National Institute of General Medical Sciences (NIGMS) P20GM103625, P30GM145393NIAID NIH HHS R01 AI087678NIAID NIH HHS R21 AI119532NIGMS NIH HHS P20 GM103625NIGMS NIH HHS P30 GM145393NIGMS NIH HHS R01 GM129325
6 · The paper itself
Abstract
Lyme disease, the leading vector-borne disease in the United States and Europe, develops after infection with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The plasmid-encoded members of paralogous gene family 52 are dispensable to the enzootic cycle of · full record | OpenQuestion